Neurosense therapeutics ltd.NRSNW.US Overview
US StockHealthcare
(No presentation for NRSNW)
NRSNW Overall Performance
NRSNW AI Analysis & Strategy
NRSNW Recent Performance
-
Neurosense therapeutics ltd.
0.81%
Avg of Sector
-1.14%
S&P500
NRSNW PowerScanner
NRSNW Key Information
NRSNW Valuation Metrics
NRSNW Earnings Table
NRSNW Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.